Overview

Albuterol HFA MDI in Pediatric Participants With Asthma

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products, R&D Inc.
Treatments:
Albuterol